GSE130404 provided a BCR-ABL expression examination of CML patients at the third month after treatment, showing a significant decrease in GSVA score of miR-342-5p in patients examined as BCR-ABL+ (Fig. 7D, lower panel). The gene discussed is ABL1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.